Get Carter, But This Must Not Be A Missed Opportunity For NHS/Industry Partnerships
This article was originally published in Clinica
Executive Summary
The UK medtech industry brands the Carter review and its NHS operating savings aims as “bold and ambitious”. Saving £5bn ($7.4bn) on non-pay NHS costs is the aim by 2020-21, and although that is less than a quarter of the projected funding shortfall that internal efficiency measures are being asked to address, the UK ABHI feels broadly positive about the initiative.
You may also be interested in...
New Mood Among UK IVDs As Ambitious Pathology Modernization Scheme Gathers Pace
NHS England's IVD and pathology sector is undergoing a major reorganization to make it fit for the future, responsive to growing demand and more patient-friendly. The plans are helping to change mindsets locally about how IVDs and pathology services should be delivered, according to speakers at a recent summit.
UK Outlook 2018: Medtech Readies For Change To FOM System Of Value-Based Procurement
For UK medtech companies, a new NHS value-based procurement system is coming in the shape of the Future Operating Model. ABHI COO Nishan Sunthares explains what the FOM will mean for UK medtechs when it applies fully later this year.
The Sustainability Stakes Are Rising: ‘We Cannot Recycle Our Way Out Of This’
The journey to Net Zero, described as ‘the defining issue of our time,’ will get harder in the coming decade. Failure to keep up the pressure will result in more long-term health conditions, increasing deaths and higher costs. The UK NHS is a Net Zero exemplar globally, but without a systemic approach, its compliance efforts could stutter.